Shots:
- ABL Bio has entered into a global licensing agreement with GSK for its Grabody-B BBB shuttle platform to develop therapies targeting various novel pathways using antibodies, siRNA, & ASOs for neurodegenerative diseases
- As per the deal, GSK will handle preclinical & clinical activities, manufacturing, & marketing of the potential programs in exchange for ~$99.4M, incl. $49.6M upfront, research milestones & potential expansion fee, with ~$2.67B in R&D, regulatory & marketing milestones, plus net sales-based tiered royalties, while ABL Bio will handle tech transfer
- Grabody-B targets IGF1R to overcome the BBB, improving drug penetration & allowing efficient drug delivery in the brain
Ref: Prnewswire | Image: ABL Bio & GSK
Related News:- ABL Bio Collaborates with Merck to Develop ABL103 Plus Keytruda for Treating Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
